These results suggested that SDHA deficiency did not affect its antitumor effects on a per–CD8+ T cell basis after allo-HCT, demonstrating the mechanisms for SDHA-KO CD8+ T cell–mediated GVT without inducing CD4+ T cell–mediated GVHD in vivo. This evidence concerns the gene CD8A and graft versus host disease.